Key result
Non-vitamin K antagonist oral anticoagulants (NOACs) inappropriate use prevalence, risk factors, and prediction models will be evaluated in a planned cross-sectional study of 1,500 elderly Chinese patients with atrial fibrillation.
Why the study?
Data specifically evaluating the real-life use of NOACs in elderly patients with AF in China are limited.
Cross-Sectional (n=1,500)
Yes
This study protocol describes a national registry designed to assess the prevalence and predictors of inappropriate NOAC dosing in elderly Chinese patients with atrial fibrillation.
May inform NOAC dosing in elderly Chinese AF patients; leaves open need for randomized outcome data.
Background: Atrial fibrillation (AF) is an arrhythmia that is prevalent globally, and its incidence grows exponentially with aging. Non-vitamin K antagonist oral anticoagulants (NOACs) have been developed in recent years, and it challenges the supremacy of warfarin for thromboembolism prophylaxis in AF. Nevertheless, there are limited data specifically evaluating the real-life use of NOACs in elderly patients with AF in China. Methods: This is a national, multicenter, non-interventional, cross-sectional study that enrolls patients with AF aged 75 years and above from 31 institutions across China. Data were collected using the Hospital Information System. The primary outcomes include (1) profiles of NOAC use in the elderly; (2) frequency of inappropriate NOAC use based on guidelines and approved labeling recommendations; (3) exploring potential risk factors related to NOACs inappropriate use; and (4) creating a prediction tool for inappropriate NOACs use. Conclusion: The results of this study reveal the prevalence, risk factors, and corresponding prediction tool of inappropriate NOACs use in older patients with AF in China, as well as provide valuable insights into the clinical application of NOACs in high-risk populations in the real-world setting. Clinical trial registration: www.ClinicalTrials.gov, identifier: NCT05361889.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2022) conducted a cross-sectional in Non-valvular atrial fibrillation (n=1,500). Non-vitamin K antagonist oral anticoagulants (NOACs) was evaluated on Profiles of NOAC use, frequency of inappropriate NOAC use, risk factors, and prediction tool. Non-vitamin K antagonist oral anticoagulants (NOACs) inappropriate use prevalence, risk factors, and prediction models will be evaluated in a planned cross-sectional study of 1,500 elderly Chinese patients with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: